FLT3 and leukemia: Targeted metabolic interventions reveal a remarkable therapeutic vulnerability: glycolysis inhibition demonstrates selective cytotoxicity against FLT3-ITD leukemic cells while sparing wild-type leukemia and normal cellular populations [74].